{"entity":{"id":"profluent-bio","kind":"company","name":"Profluent","aka":[],"tldr":"Profluent uses protein language models to design new gene editors (OpenCRISPR-1) and antibodies.","summary":"Profluent, based in Berkeley, uses protein language models to design new gene editors and antibodies. Its OpenCRISPR-1, released in 2024, was the first AI-generated gene editor released openly, and the ProGen family of models underpins its designs. OnCo links it to de novo designed protein binders. Whether AI-designed editors and binders offer advantages in specificity or manufacturability that justify their novelty is the open question for cancer applications. The de novo protein binder page carries the wider field.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.profluent.bio"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["de-novo-protein-design","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Berkeley, CA","country":"US","companyType":"ai-software","website":"https://www.profluent.bio","investors":[],"funding":[]},"route":"/companies/profluent-bio/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/"}]}}